TET2 Mutation as a Prognostic Marker in Pediatric AML: A Leukemia Biology Study of AAML0531 From the Children's Oncology Group

Grant

Date/time Interval

  • March 1, 2012 - December 31, 2015
  • Total Award Amount

  • 60000.00
  • Direct Costs

  • 60000.00
  • Sponsor Award Id

  • Contributor

  • Kutny M.D., Matthew   Principal Investigator